SG10201913260VA - Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same - Google Patents

Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

Info

Publication number: SG10201913260VA
Authority: SG; Singapore
Prior art keywords: preparing; same; heterodimeric bispecific; antibody; bispecific antibody
Prior art date: 2016-11-18

Application number

SG10201913260VA

Inventor

Jiawang Liu

Nanmeng Song

Yaping Yang

Maengsup Kim

Original Assignee

Beijing Hanmi Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-18

Filing date

2017-11-16

Publication date

2020-03-30

2017-11-16 Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd

2020-03-30 Publication of SG10201913260VA publication Critical patent/SG10201913260VA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SG10201913260VA 2016-11-18 2017-11-16 Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same SG10201913260VA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN201611016435		2016-11-18

Publications (1)

Publication Number	Publication Date
SG10201913260VA true SG10201913260VA (en)	2020-03-30

Family

ID=62146170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201913260VA SG10201913260VA (en)	2016-11-18	2017-11-16	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same

Country Status (19)

Country	Link
US (1)	US11319378B2 (en)
EP (1)	EP3533804A4 (en)
JP (1)	JP7031810B2 (en)
KR (1)	KR102247704B1 (en)
CN (1)	CN109963876B (en)
AU (1)	AU2017359813B2 (en)
BR (1)	BR112019010051A2 (en)
CA (1)	CA3043652A1 (en)
CL (1)	CL2019001352A1 (en)
CO (1)	CO2019005101A2 (en)
DO (1)	DOP2019000124A (en)
EA (1)	EA201990894A9 (en)
EC (1)	ECSP19035482A (en)
MX (1)	MX2019005858A (en)
PE (1)	PE20191080A1 (en)
PH (1)	PH12019501089A1 (en)
SG (1)	SG10201913260VA (en)
TN (1)	TN2019000161A1 (en)
WO (1)	WO2018090950A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3035681A1 (en)	2016-09-29	2018-04-05	Beijing Hanmi Pharmaceutical Co., Ltd.	Heterodimeric immunoglobulin constructs and preparation methods thereof
CN109963876B (en)	2016-11-18	2023-11-14	北京韩美药品有限公司	Anti-PD-1/anti-HER2 natural antibody structure-like heterodimer form bispecific antibody and its preparation
CA3084626A1 (en) *	2017-12-04	2019-06-13	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019153200A1 (en)	2018-02-08	2019-08-15	北京韩美药品有限公司	Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
KR20210088611A (en) *	2018-11-05	2021-07-14	베이징 한미 파마슈티컬 컴퍼니 리미티드	Heterodimeric bispecific antibody in the form of anti-TNFα/anti-IL-17A natural antibody structure and method for preparing the same
CN111196856A (en) *	2018-11-19	2020-05-26	三生国健药业（上海）股份有限公司	anti-HER 2/PD1 bispecific antibodies
CN111378045B (en) *	2018-12-28	2022-08-02	长春金赛药业有限责任公司	Bivalent and bispecific antibody, preparation method thereof, encoding gene, host cell and composition
CN114206382B (en) *	2019-08-07	2024-03-26	信达生物制药(苏州)有限公司	Preparations containing anti-PD-1/HER2 bispecific antibodies and preparation methods and uses thereof
CN111995685B (en) *	2020-04-30	2022-03-08	中国科学院上海药物研究所	Bispecific antibody targeting HER2 and PD-1 and application thereof
WO2024061223A1 (en) *	2022-09-20	2024-03-28	普米斯生物技术(珠海)有限公司	Antibody and use thereof in resisting tumor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9100352A (en)	1991-02-27	1992-09-16	Hoogovens Groep Bv	METHOD FOR MANUFACTURING IRON FOIL BY ELECTRODE POSITION.
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en) *	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
ES2292682T3 (en) *	1998-05-06	2008-03-16	Genentech, Inc.	PURIFICATION OF ANTIBODIES THROUGH IONIC EXCHANGE CHROMATOGRAPHY.
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2006031994A2 (en)	2004-09-14	2006-03-23	Xencor, Inc.	Monomeric immunoglobulin fc domains
CN104945508B (en)	2007-06-18	2019-02-22	默沙东有限责任公司	For the antibody of people's programmed death receptor PD-1
PT2235064E (en)	2008-01-07	2016-03-01	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102405230A (en)	2009-04-22	2012-04-04	默克专利有限公司	Antibody fusion proteins with modified fcrn binding sites
US9200060B2 (en)	2009-11-23	2015-12-01	Amgen Inc.	Monomeric antibody Fc
CN108341868B (en)	2010-11-05	2022-06-07	酵活有限公司	Antibody design for stable heterodimerization with mutations in the Fc domain
US9683052B2 (en)	2011-03-25	2017-06-20	Glenmark Pharmaceuticals S.A.	Hetero-dimeric immunoglobulins
RU2625034C2 (en)	2011-04-20	2017-07-11	МЕДИММЬЮН, ЭлЭлСи	Antibodies and other molecules binding b7-h1 and pd-1
WO2013060867A2 (en)	2011-10-27	2013-05-02	Genmab A/S	Production of heterodimeric proteins
CN109897103B (en)	2011-11-04	2024-05-17	酵活英属哥伦比亚有限公司	Stable heterodimeric antibody design with mutations in the Fc domain
SG10201913376XA (en)	2012-04-20	2020-02-27	Merus Nv	Methods and means for the production of ig-like molecules
US20150239991A1 (en)	2012-09-25	2015-08-27	Glenmark Pharmaceuticals S.A.	Purification of hetero-dimeric immunoglobulins
EP2914634B1 (en)	2012-11-02	2017-12-06	Zymeworks Inc.	Crystal structures of heterodimeric fc domains
US9914785B2 (en)	2012-11-28	2018-03-13	Zymeworks Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
AU2013351888C1 (en)	2012-11-28	2018-10-11	Zymeworks Bc Inc.	Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
ES2784631T3 (en)	2012-12-03	2020-09-29	Novimmune Sa	Anti-CD47 antibodies and methods of using them
CA2920113A1 (en) *	2013-08-20	2015-02-26	Merck Sharp & Dohme Corp.	Treating cancer with a combination of a pd-1 antagonist and dinaciclib
EP3083692B1 (en)	2013-12-17	2020-02-19	F.Hoffmann-La Roche Ag	Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
WO2015095412A1 (en)	2013-12-19	2015-06-25	Zhong Wang	Bispecific antibody with two single-domain antigen-binding fragments
TWI681969B (en)	2014-01-23	2020-01-11	美商再生元醫藥公司	Human antibodies to pd-1
JOP20200094A1 (en)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	Antibody Molecules of PD-1 and Their Uses
PT3180363T (en)	2014-08-15	2019-11-05	Merck Patent Gmbh	Sirp-alpha immunoglobulin fusion proteins
WO2016057933A1 (en)	2014-10-10	2016-04-14	Global Biopharma, Inc.	Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
KR102489471B1 (en)	2014-12-30	2023-01-18	셀진 코포레이션	Anti-CD47 Antibodies and Uses Thereof
BR112017015136A2 (en) *	2015-01-14	2018-01-30	Compass Therapeutics Llc	multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit
WO2016170039A1 (en)	2015-04-23	2016-10-27	F. Hoffmann-La Roche Ag	Combination therapy of antibody binding to angiopoietin 2 with antibody binding to programmed death 1 polypeptide
TWI870335B (en)	2015-06-12	2025-01-21	美商宏觀基因股份有限公司	Variant chimeric 4d5 antibodies and uses thereof in combination with anti-pd-1 antibodies for the treatment of cancer
CN105111314B (en)	2015-08-13	2019-01-08	成都百世博生物技术有限公司	Novel fusion protein, pharmaceutical composition, preparation method and application thereof
CN105175545B (en)	2015-10-20	2019-01-25	安徽瀚海博兴生物技术有限公司	An anti-VEGF-anti-PD-1 bifunctional antibody and its application
CN106883297B (en)	2015-12-16	2019-12-13	苏州康宁杰瑞生物科技有限公司	CH3 domain-based heterodimer molecule, preparation method and application thereof
EP3397646A1 (en)	2015-12-28	2018-11-07	Massachusetts Institute of Technology	Bispecific antibodies having constant region mutations and uses therefor
WO2017167350A1 (en)	2016-03-30	2017-10-05	Horst Lindhofer	Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
GB201611530D0 (en)	2016-07-01	2016-08-17	Alligator Bioscience Ab	Novel polypeptides
CA3035681A1 (en)	2016-09-29	2018-04-05	Beijing Hanmi Pharmaceutical Co., Ltd.	Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3383915A4 (en)	2016-10-15	2019-07-24	Innovent Biologics (Suzhou) Co., Ltd.	ANTI-PD-1 ANTIBODIES
CN109963876B (en)	2016-11-18	2023-11-14	北京韩美药品有限公司	Anti-PD-1/anti-HER2 natural antibody structure-like heterodimer form bispecific antibody and its preparation
SG10201913676QA (en)	2017-04-01	2020-03-30	Beijing hanmi pharm co ltd	Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
AR112603A1 (en)	2017-07-10	2019-11-20	Lilly Co Eli	BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS
CN107325184A (en)	2017-08-08	2017-11-07	安徽大学	Bispecific antibody targeting EGFR and HER2 and application thereof
EA039662B1 (en)	2017-10-03	2022-02-24	Закрытое Акционерное Общество "Биокад"	Antibodies specific to cd47 and pd-l1
CA3084626A1 (en)	2017-12-04	2019-06-13	Beijing Hanmi Pharmaceutical Co., Ltd.	Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof
WO2019153200A1 (en)	2018-02-08	2019-08-15	北京韩美药品有限公司	Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
KR20200120927A (en)	2018-02-11	2020-10-22	베이징 한미 파마슈티컬 컴퍼니 리미티드	Anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric bispecific antibody and preparation thereof

2017
- 2017-11-16 CN CN201780071590.9A patent/CN109963876B/en active Active
- 2017-11-16 PE PE2019001036A patent/PE20191080A1/en unknown
- 2017-11-16 US US16/461,646 patent/US11319378B2/en active Active
- 2017-11-16 TN TNP/2019/000161A patent/TN2019000161A1/en unknown
- 2017-11-16 BR BR112019010051A patent/BR112019010051A2/en active Search and Examination
- 2017-11-16 SG SG10201913260VA patent/SG10201913260VA/en unknown
- 2017-11-16 EP EP17871719.5A patent/EP3533804A4/en active Pending
- 2017-11-16 EA EA201990894A patent/EA201990894A9/en unknown
- 2017-11-16 KR KR1020197013134A patent/KR102247704B1/en active Active
- 2017-11-16 JP JP2019527168A patent/JP7031810B2/en active Active
- 2017-11-16 WO PCT/CN2017/111310 patent/WO2018090950A1/en active Application Filing
- 2017-11-16 AU AU2017359813A patent/AU2017359813B2/en active Active
- 2017-11-16 MX MX2019005858A patent/MX2019005858A/en unknown
- 2017-11-16 CA CA3043652A patent/CA3043652A1/en active Pending
2019
- 2019-05-16 PH PH12019501089A patent/PH12019501089A1/en unknown
- 2019-05-17 CL CL2019001352A patent/CL2019001352A1/en unknown
- 2019-05-17 CO CONC2019/0005101A patent/CO2019005101A2/en unknown
- 2019-05-17 EC ECSENADI201935482A patent/ECSP19035482A/en unknown
- 2019-05-17 DO DO2019000124A patent/DOP2019000124A/en unknown

Also Published As

Publication number	Publication date
AU2017359813B2 (en)	2024-12-05
CN109963876B (en)	2023-11-14
EA201990894A9 (en)	2019-11-27
JP2020510407A (en)	2020-04-09
CN109963876A (en)	2019-07-02
US11319378B2 (en)	2022-05-03
KR102247704B1 (en)	2021-05-03
ECSP19035482A (en)	2019-05-31
EP3533804A1 (en)	2019-09-04
PE20191080A1 (en)	2019-08-20
JP7031810B2 (en)	2022-03-08
EA201990894A1 (en)	2019-09-30
TN2019000161A1 (en)	2020-10-05
CO2019005101A2 (en)	2019-05-31
CL2019001352A1 (en)	2019-08-02
EP3533804A4 (en)	2020-06-17
MX2019005858A (en)	2019-08-12
PH12019501089A1 (en)	2020-03-02
BR112019010051A2 (en)	2019-09-03
WO2018090950A1 (en)	2018-05-24
AU2017359813A1 (en)	2019-05-30
CA3043652A1 (en)	2018-05-24
US20190367633A1 (en)	2019-12-05
KR20190065375A (en)	2019-06-11
DOP2019000124A (en)	2019-11-15

Publication	Publication Date	Title
IL289946A (en)	2022-03-01	Bispecific antibodies against cd3 and cd20
SG10201913260VA (en)	2020-03-30	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
IL279053A (en)	2021-01-31	Anti-pvrig/anti-tigit bispecific antibodies and methods of use
HK1258304A1 (en)	2019-11-08	Optimized anti-cd3 bispecific antibodies and uses thereof
ZA201900792B (en)	2020-03-25	Anti-pd-1 antibodies, method for producing same and method for using same
SG11202100252SA (en)	2021-02-25	BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
IL283530A (en)	2021-07-29	Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
SG11201705252UA (en)	2017-07-28	Anti-pd-1 monoclonal antibodies and obtaining method thereof
EP3527590A4 (en)	2020-05-27	Anti-egfr and anti-cd3 bispecific antibody and applications thereof
HK1251969A1 (en)	2019-05-10	Anti-her2 antibodies and methods of use
IL255076A0 (en)	2017-12-31	Bispecific antibody constructs for cdh3 and cd3
ZA202004595B (en)	2024-09-25	Bispecific antibody construct directed to muc17 and cd3
ZA201906457B (en)	2020-08-26	Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
EP3735429A4 (en)	2021-10-06	Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
ZA202003858B (en)	2021-07-28	Monoclonal antibodies and methods for using same
IL271346A (en)	2020-01-30	Bispecific antibodies and methods of making and using thereof
EP3645740A4 (en)	2021-08-18	Anti-pd-1 antibodies and methods of making and using thereof
IL284026A (en)	2021-08-31	Methods of producing heterodimeric antibodies
EP3710482A4 (en)	2021-08-18	Compositions and methods for making and using bispecific antibodies
SG10201603290RA (en)	2017-11-29	Antibody Composition And Method For Producing The Same